Solara Active Pharma Sciences - PP
add_icon

Solara Active Pharma Sciences - PP

381.70
-3.15
(-0.82%)
Market Cap
₹- Cr
PE Ratio
-
Volume
15.00
Day High - Low
₹387.15 - ₹381.70
52W High-Low
₹524.90 - ₹330.00
ann
There are new updates from the company16 hours ago
Viewcross
right
hide
Key Fundamentals
Add Ratio
split_icon_default
Market Cap
- Cr
EPS
-
PB Ratio
-
Book Value
134.75
EBITDA
-
Dividend Yield
- %
Industry
Healthcare
ROE Growth %
-
Debt to Equity
-
Forecast For
Actual

Company News

View All News
Caret
negative
Solara Active Pharma Sciences reported quarterly results with revenue declining 2% to INR 314 crores. EBITDA dropped 39% to INR 35 crores due to an unscheduled 3-4 week operational shutdown at the Mangalore facility for upgrades. The shutdown resulted in lost sales of INR 30-35 crores and gross margin impact of INR 18-20 crores. Despite disruptions, gross margin remained at 51% and regulated markets contributed 75% of sales. The company successfully cleared a U.S. FDA audit with only 2 minor observations. Operating costs increased by INR 9 crores, including INR 4 crores in one-time upgrade costs. Management expects the disruption to be temporary and maintains outlook of 10% revenue growth and 15-20% EBITDA growth. Debt was reduced by INR 153 crores during the first half, with plans to further reduce debt to INR 446 crores by Q1 FY27. The company has 90-95 DMF filings in the U.S. with 35-40 active products.
neutral
Solara Active Pharma Sciences Limited submitted its monitoring agency report for the quarter ended September 30, 2025, regarding the utilization of proceeds from its rights issue. The company raised Rs 449.95 crore through the rights issue conducted from May 28, 2024 to June 11, 2024, with net proceeds of Rs 446.95 crore. CRISIL Ratings Limited, serving as the monitoring agency, confirmed no deviation from the stated objectives in the Letter of Offer. The proceeds were allocated for two main purposes: Rs 334.71 crore for repayment of outstanding borrowings and Rs 112.24 crore for general corporate purposes. As of September 30, 2025, Rs 233.61 crore was utilized for debt repayment and Rs 15.83 crore for general corporate purposes, specifically vendor payments including settlement of legacy payables from previous financial years. The company has Rs 138.37 crore in unutilized proceeds, comprising funds yet to be raised through a second call and small amounts pending receipt.
neutral
Solara Active Pharma Sciences Allots 8,040 Equity Shares Under Employee Stock Option PlanNov 06, 2025
Solara Active Pharma Sciences Limited's Board of Directors approved the allotment of 8,040 equity shares with a face value of Rs. 10 each under the Solara Employee Stock Option Plan 2018. The allotment was made against the exercise of vested options by employees. The company realized Rs. 30,15,000 from the exercise of these options. Following this allotment, the company's paid-up share capital increased from Rs. 44,47,93,723.50 to Rs. 44,48,74,123.50. The newly issued shares rank pari-passu with existing equity shares in all respects. The diluted earnings per share following the issuance is Rs. 19 per share. Options under the plan must be exercised within 120 days from the vesting date.
View more
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
790.15
-
#1 -
-
-
-
-
34.61
699.20
-
#1 -
-
-
-
-
43.29
64.57
-
#1 -
-
-
-
-
21.03
554.80
-
#1 -
-
-
-
-
37.85
28,850.00
-
#1 -
-
-
-
-
39.24
42.05
-
#1 -
-
-
-
-
41.15
54.60
-
#1 -
-
-
-
-
42.72
5,001.00
-
#1 -
-
-
-
-
43.40
414.10
-
#1 -
-
-
-
-
43.97
26.95
-
#1 -
-
-
-
-
41.68
Growth Rate
Revenue Growth
-
Net Income Growth
-
Cash Flow Change
-
ROE
-
ROCE
-
EBITDA Margin (Avg.)
-

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
20 Sept 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
20 Sept 2024 389.75 415.05

Announcements

Clarification On Volume Movement16 hours ago
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 19, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptNov 11, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 06, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportNov 06, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 05, 2025
General-UpdatesNov 05, 2025
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSNov 05, 2025
Statement Of Deviation And Variation For Funds Raised Under Rights Issue For The Quarter Ended September 30 2025.Nov 05, 2025
Intimation Regarding The Grant Of ESOPNov 05, 2025
Intimation About Appointment Of Mr. Mohanraj S As Chief Human Resources Officer (CHRO)Nov 05, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseNov 05, 2025
Announcement under Regulation 30 (LODR)-Resignation of DirectorNov 05, 2025
Board Meeting Outcome For Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025.Nov 05, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationOct 30, 2025
ESG Rating By CRISILOct 17, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 16, 2025
Announcement under Regulation 30 (LODR)-AllotmentOct 13, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 09, 2025
Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 29, 2025
Closure of Trading WindowSep 26, 2025
Announcement Under Regulation 30 SEBI (LODR) - ClarificationSep 26, 2025
Shareholder Meeting / Postal Ballot-Outcome of AGMSep 25, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 03, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 03, 2025
Business Responsibility and Sustainability Reporting (BRSR)Sep 02, 2025
Reg. 34 (1) Annual Report.Sep 02, 2025
Notice Of The 8Th Annual General MeetingSep 02, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 01, 2025
Intimation Regarding 100 Days Campaign - Saksham NiveshakAug 21, 2025
Receipt Of Call Money Pursuant To The First Reminder Notice Issued For Payment Of First Call Money On The Outstanding Partly Paid-Up Rights Equity Shares Of The Company.Aug 16, 2025
Announcement under Regulation 30 (LODR)-Monitoring Agency ReportAug 13, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptJul 29, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 26, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeJul 25, 2025
Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJul 25, 2025
Statement Of Deviation And Variation For Funds Raised Under Rights Issue For The Quarter Ended June 30 2025.Jul 25, 2025
Board Meeting Outcome For Unaudited Financial Results For The Quarter Ended June 30 2025.Jul 25, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationJul 21, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 17, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 07, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 03, 2025
Dispatch Of First Reminder Notice For Payment Of First Call MoneyJul 02, 2025
Announcement under Regulation 30 (LODR)-Credit RatingJul 01, 2025
Closure of Trading WindowJun 27, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 28, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 28, 2025
Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 21, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 16, 2025
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 15, 2025

Technical Indicators